HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olinger, G. N. Articles by Malik, M. I. Search for Related Content PubMed PubMed Citation Articles by Olinger, G. N. Articles by Malik, M. I.

The Journal of Thoracic and Cardiovascular Surgery, Vol 87, 673-677, Copyright © 1984 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Cardiopulmonary bypass for patients with previously documented heparin- induced platelet aggregation

GN Olinger, CV Hussey, JA Olive and MI Malik

Heparin-dependent intravascular coagulation is a widely recognized syndrome in which heparin acts as a hapten for an antiplatelet antibody and causes accelerated intravascular thrombosis and thrombocytopenia that may culminate in organ loss, hemorrhagic diathesis, and even death. Diagnosis is made in vitro by observing heparin-stimulated aggregation of normal platelets suspended in the patient's platelet- poor plasma. Treatment consists of cessation of heparin and use of antiaggregating agents with or without warfarin sodium. Management of patients with prior heparin-dependent intravascular coagulation who require cardiopulmonary bypass has not been reported. We now have successfully managed three such patients and herein present guidelines for management. Each patient was undergoing heparin therapy and manifested hallmark heparin tachyphylaxis, thrombocytopenia, and increased thrombotic symptoms (further venous thrombosis after cardiac catheterization in two cases and exacerbation of unstable angina in the other). In vitro aggregation studies were abnormal. Heparin was stopped, and antiaggregative therapy was begun with good response in each instance. In vitro studies were done serially until the antiplatelet antibody reaction had vanished (usually 4 to 8 weeks), and coronary revascularization was then conducted with full heparinization. Further heparin exposure postoperatively was avoided. There was no perioperative evidence of intravascular thrombosis or bleeding diathesis, and in vitro heparin-dependent aggregation did not recur. We conclude that patients with previously documented heparin-dependent intravascular coagulation can safely sustain the massive heparin rechallenge of cardiopulmonary bypass, provided that in vitro aggregation has ceased and rechallenge therapy is not prolonged.

This article has been cited by other articles:

				T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]

				A. T. Gurbuz, W. G. Elliott, and A. A. Zia Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149. [Abstract] [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 311S - 337S. [Abstract] [Full Text] [PDF]

				U. Dandekar, J. Young, M. Kalkat, and C. M.R. Satur Heparin induced thrombocytopenia type II complicating coronary artery bypass surgery: a tale of caution Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 121 - 123. [Abstract] [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., December 1, 2003; 76(6): 2121 - 2131. [Abstract] [Full Text] [PDF]

				R. A. Saad, E. Pravinkumar, and N. R. Webster HIT/HITT and alternative anticoagulation: current concepts Br. J. Anaesth., October 1, 2003; 91(4): 606 - 607. [Full Text] [PDF]

				T. E. Warkentin and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann. Thorac. Surg., August 1, 2003; 76(2): 638 - 648. [Abstract] [Full Text] [PDF]

				S. Selleng, N. Lubenow, H.-G. Wollert, B. Mullejans, and A. Greinacher Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin Ann. Thorac. Surg., March 1, 2001; 71(3): 1041 - 1042. [Abstract] [Full Text] [PDF]

				A. Aouifi, P. Blanc, V. Piriou, O. H. Bastien, P. Ffrench, M. Hanss, and J.-J. Lehot Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia Ann. Thorac. Surg., February 1, 2001; 71(2): 678 - 683. [Abstract] [Full Text] [PDF]

				K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders Hematology, January 1, 2001; 2001(1): 282 - 305. [Abstract] [Full Text] [PDF]

				M. P Reilly, R. Weiss, A. Askenase, C. Tuite, M. Soulen, and E. R Mohler III Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia Vascular Medicine, November 1, 2000; 5(4): 239 - 242. [Abstract] [PDF]

				J. M. Walenga, J. Fareed, R. L. Bick, and R. Pifarre New Anticoagulants for the Cardiovascular Patient Clinical and Applied Thrombosis/Hemostasis, January 1, 1995; 1(1): 24 - 30. [Abstract] [PDF]

				M. Sobel Heparin-Induced Thrombocytopenia Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 1 - 27. [PDF]